Literature DB >> 31369883

Extent of Resection and Long-Term Survival of Pineal Region Tumors in Helsinki Neurosurgery.

Joham Choque-Velasquez1, Julio Resendiz-Nieves2, Behnam Rezai Jahromi2, Roberto Colasanti3, Rahul Raj2, Juho Vehviläinen2, Olli Tynninen4, Juhani Collan5, Mika Niemelä2, Juha Hernesniemi6.   

Abstract

BACKGROUND: Pineal region tumors represent challenging surgical lesions with wide ranges of survival reported in different surgical series. In this article, we emphasize the role of complete microsurgical resection (CMR) to obtain a favorable long-term outcome of pineal region tumors.
METHODS: We report a retrospective study of pineal region tumors operated on in Helsinki Neurosurgery between 1997 and 2015. Information was obtained from the hospital records, and an evaluation of the Finnish population register was conducted in July 2018 to determine the current status of the patients.
RESULTS: A total of 76 pineal region tumors were operated on. The survival was 62% at a mean follow-up of 125 ± 105 months (range, 0-588 months), and the disease-related mortality was limited to 14 patients (18.4%). Up to July 2018, 29 patients had died. Two patients died 1 and 3 months after surgery of delayed thalamic infarctions, 12 patients of disease progression, and 15 had non-disease-related deaths. Only 1 patient was lost in the long-term follow-up. Ten of 14 disease-related deaths occurred during the first 5 years of follow-up: 5 diffuse gliomas, 3 germ cell tumors, 1 grade II-III pineal parenchymal tumor of intermediate differentiation, and 1 meningioma. CMR was linked to better tumor-free survival and long-term survival, with the exception of diffuse gliomas.
CONCLUSIONS: CMR, in the setting of a multidisciplinary management of pineal region tumors, correlates with favorable survival and with minimal mortality. Surgically treated grade II-IV gliomas constitute a particular group with high mortality within the first 5 years independently of the microsurgical resection.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Microneurosurgery; Multidisciplinary management; Pineal region lesions; Pineal tumors; Radiochemotherapy; Sitting position; Supracerebellar infratentorial approach

Mesh:

Year:  2019        PMID: 31369883     DOI: 10.1016/j.wneu.2019.07.169

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Role of proliferative marker index and KBTBD4 mutation in the pathological diagnosis of pineal parenchymal tumors.

Authors:  Eita Uchida; Atsushi Sasaki; Mitsuaki Shirahata; Tomonari Suzuki; Jun-Ichi Adachi; Kazuhiko Mishima; Masanori Yasuda; Takamitsu Fujimaki; Koichi Ichimura; Ryo Nishikawa
Journal:  Brain Tumor Pathol       Date:  2022-01-09       Impact factor: 3.298

Review 2.  Pineal parenchymal tumor of intermediate differentiation: a systematic review and contemporary management of 389 cases reported during the last two decades.

Authors:  Hajime Takase; Reo Tanoshima; Navneet Singla; Yoshihiko Nakamura; Tetsuya Yamamoto
Journal:  Neurosurg Rev       Date:  2021-10-20       Impact factor: 3.042

3.  Mixed germ cell tumor of the pineal gland in a pediatric patient.

Authors:  Serbeze Kabashi; Ilir Ahmetgjekaj; Edlira Harizi; Fjolla Hyseni; Erisa Kola; Valon Vokshi; Guri Hyseni; Ina Kola; Humza Haroon; Masum Rahman; Kledisa Shemsi; Arlind Decka; Livia Capi; Kaltrina Goçaj; Juna Musa
Journal:  Radiol Case Rep       Date:  2022-06-17

4.  Incidence, Prognostic Factors, and Survival Trend in Pineal Gland Tumors: A Population-Based Analysis.

Authors:  Huy Gia Vuong; Tam N M Ngo; Ian F Dunn
Journal:  Front Oncol       Date:  2021-11-19       Impact factor: 6.244

Review 5.  Supratentorial Pediatric Midline Tumors and Tumor-like Lesions: Clinical Spectrum, Natural History and Treatment Options.

Authors:  Luca Paun; Alexandre Lavé; Gildas Patet; Andrea Bartoli
Journal:  Children (Basel)       Date:  2022-04-09

Review 6.  Pineal Gland Tumors: A Review.

Authors:  Gaia Favero; Francesca Bonomini; Rita Rezzani
Journal:  Cancers (Basel)       Date:  2021-03-27       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.